Why Impel NeuroPharma Stock Blasted 27% Higher Thursday
After three consecutive days of declines that saw its shares crater from nearly $34 per share to less than half that figure, Impel NeuroPharma (NASDAQ: IMPL) rocketed more than 27% higher on Thursday. With some recent good news about the company, investors were obviously pouncing on that weakened stock price.
The sell-off in the previous days wasn't necessary warranted, as recent developments for the company have generally been quite favorable. Chief among these was last Friday's announcement that the Food and Drug Administration had approved the company's lead candidate, migraine headache treatment Trudhesa.
Image source: Getty Images.
Source Fool.com
